Rafael C. Moreno
Barcelona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 43 publications
Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 12, 2026
Oncolytic adenovirus incorporating TetO sites in the E1A promoter for controlled replication in TetR-expressing mesenchymal stem cells.
Journal: Molecular therapy. Oncology
Published: February 06, 2026
Biocompatible self-illuminating sphingomyelin nanosystems for photodynamic-based cancer therapy.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: February 28, 2025
Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 20, 2024
Clinical protocol phase II study of tumor infiltrating lymphocytes in advanced tumors with alterations in the SWI/SNF complex: the TILTS study.
Journal: Future oncology (London, England)
Published: August 12, 2024
Oncolytic adenovirus coding for shedding-resistant MICA enhances immune responses against tumors.
Journal: Cancer immunology, immunotherapy : CII
Published: August 23, 2023
SWI/SNF Complex Alterations in Tumors with Rhabdoid Features: Novel Therapeutic Approaches and Opportunities for Adoptive Cell Therapy.
Journal: International journal of molecular sciences
Published: May 31, 2023
Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models.
Journal: Journal of translational medicine
Published: May 11, 2023
Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors.
Journal: Journal for immunotherapy of cancer
Published: March 01, 2022
VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects.
Journal: Journal for immunotherapy of cancer
Published: September 11, 2021
Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition.
Journal: Molecular therapy oncolytics
Published: September 03, 2021
Last Updated: 09/26/2026